%0 Journal Article
%A Schweitzer, Finja
%A Laurent, Sarah
%A Fink, Gereon Rudolf
%A Barnett, Michael H.
%A Reddel, Stephen
%A Hartung, Hans-Peter
%A Warnke, Clemens
%T Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis
%J Current opinion in neurology
%V 32
%N 3
%@ 1350-7540
%C [S.l.]
%I Ovid
%M FZJ-2019-02818
%P 305 - 312
%D 2019
%X A variety of high-efficacy disease-modifying therapies (DMTs) are available for the treatment of multiple sclerosis (MS). After evaluation and approval by regulatory agencies, DMTs are likely to be administered to patients whose characteristics differ from those enrolled in clinical trials. This may contribute to the emergence of unexpected adverse events observed in the real-world setting. Higher age may be a relevant factor that could change the benefit–risk balance of DMTs, as it may associate with lower efficiency and higher frequency of adverse events.
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:30985373
%U <Go to ISI:>//WOS:000480723400001
%R 10.1097/WCO.0000000000000701
%U https://juser.fz-juelich.de/record/862515